AcelRx Pharmaceuticals (ACRX) Earns Media Sentiment Score of 0.05
News articles about AcelRx Pharmaceuticals (NASDAQ:ACRX) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 46.005177216127 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) – Featured Volatile Stock – The Investor Guide (wallstreetnews24.com)
- AcelRx Pharmaceuticals, Inc. (ACRX) registers a price change of -3.03% while Novartis AG (NVS) finishes with a flow … – Stocks Gallery (stocksgallery.com)
- AcelRx Upcoming FDA Review, Analyst Target Price and Pipeline Review (finance.yahoo.com)
- ETFs with exposure to AcelRx Pharmaceuticals, Inc. : September 11, 2017 (finance.yahoo.com)
- AcelRx Pharmaceuticals, Inc. (ACRX) CFO Acquires $22,680.00 in Stock (americanbankingnews.com)
ACRX has been the subject of several analyst reports. Royal Bank Of Canada set a $6.00 price objective on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 25th. ValuEngine downgraded AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Piper Jaffray Companies set a $3.00 price objective on AcelRx Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, July 25th. Roth Capital set a $13.00 price objective on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Finally, Stifel Nicolaus raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $7.50.
AcelRx Pharmaceuticals (ACRX) remained flat at $3.25 on Wednesday. The company had a trading volume of 106,187 shares. The stock’s market capitalization is $147.48 million. AcelRx Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $4.08. The stock’s 50-day moving average price is $3.18 and its 200 day moving average price is $2.80.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.01). The business had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. On average, equities research analysts forecast that AcelRx Pharmaceuticals will post ($1.13) EPS for the current fiscal year.
In other AcelRx Pharmaceuticals news, insider Pamela P. Palmer purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average price of $2.95 per share, with a total value of $29,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $2.40, for a total value of $2,100,000.00. The disclosure for this sale can be found here. Insiders have bought 37,000 shares of company stock worth $112,280 in the last ninety days. Corporate insiders own 28.10% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.